Characterizing the subjective, psychomotor, and physiological effects of a hydrocodone combination product (Hycodan) in non-drug-abusing volunteers

Psychopharmacology

Volumn 165, Issue 2, 2003, Pages 146-156

  Zacny, James P ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Abuse liability; Human; Hydrocodone; Opioid; Subjective

Indexed keywords

HOMATROPINE; HYDROCODONE; HYDROCODONE BITARTRATE; LORAZEPAM; MORPHINE; OPIATE;

ADULT; ANALGESIA; ANTICHOLINERGIC EFFECT; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; COUGHING; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MEASUREMENT; MIOSIS; NORMAL HUMAN; POPULATION; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; PSYCHOMOTOR DISORDER; STATISTICAL SIGNIFICANCE; VOLUNTEER;

ADULT; AROUSAL; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HUMANS; HYDROCODONE; LORAZEPAM; MALE; MORPHINE; PSYCHOMOTOR PERFORMANCE; REACTION TIME; RISK; SUBSTANCE-RELATED DISORDERS; TROPANES;

EID: 0037217790     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-002-1245-5     Document Type: Article

References (49)

1. Baddeley AD (1968) A three-minute reasoning test based on grammatical transformation. Psychonom Sci 10:341-342
2. Beaver WT, McMillan D (1980) Methodology considerations in the evaluation of analgesic combinations: Acetaminophen (paracetamol) and hydrocodone in postpartum pain. Br J Clin Pharmacol 10:215S-223S
3. Black ML, Hill JL, Zacny JP (1999) Behavioral and physiological effects of remifentanil and alfentanil in healthy volunteers. Anesthesiology 90:718-726
4. Cole JO, Orzack MH, Beake B, Bird M, Bar-Tal Y (1982) Assessment of the abuse liability of buspirone in recreational sedative users. J Clin Psychiatry 43:69-75
5. Curran HV, Allen D, Lader M (1987) The effects of single doses of alpidem and lorazepam on memory and psychomotor performance in normal volunteers. J Psychopharmacol 2:81-89
6. Dykstra LA, Preston KL. Bigelow GE (1997) Discriminative stimulus and subjective effects of opioids with mu and kappa activity: Data from laboratory animals and human subjects. Psychopharmacology 130:14-27
7. Food and Drug Administration. National Drug Code Directory, December, 2001. http://www.fda.gov/cder/ndc/database/default.htm
8. Fraser HF, Isbell H (1950) Addiction liabilities of morphinan, 6-methyldihydromorphine and dihydrocodeinone. J Pharmacol Exp Ther 100:128-135
9. Fraser HF, van Horn GD, Martin WR, Wolbach AB, Isbell H (1961) Methods for evaluating addiction liability. (a) "attitude" of opiate addicts toward opiate-like drugs, (b) a short-term "direct" addiction test. J Pharmacol Exp Ther 133:371-387
10. Haertzen CA (1966) Development of scales based on patterns of drug effects, using the Addiction Research Center Inventory (ARCI). Psychol Rep 18:163-194
11. Hannington-Kiff JG (1970) Measurement of recovery from outpatient general anaesthesia with a simple ocular test. Br Med J 3:132-135
12. Hayes AH, Katz RA (1970) Homatropine bradycardia in man. Clin Pharmacol Ther 11:558-566
13. Hennies HH, Friderichs E, Schneider J (1988) Receptor binding, analgesic and antitussive potency of tramadol and other selected opioids. Arzneimittelforschung 38:877-880
14. Hill JL, Zacny JP (2000) Comparing the subjective, psychomotor, and physiological effects of intravenous hydromorphone and morphine in normal volunteers. Psychopharmacology 152:31-39
15. Hopkinson JH (1978) Hydrocodone - A unique challenge for an established drug: Comparison of repeated oral doses of hydrocodone (10 mg) and codeine (60 mg) in the treatment of postpartum pain. Curr Res Ther 24:503-516
16. Jasinski DR, Henningfield JE (1989) Human abuse liability assessment by measurement of subjective and physiological effects. In: Fischman MW, Mello NK (eds) Testing for abuse liability of drugs in humans. NIDA Research Monograph Series 92, Rockville, Md. pp 73-100
17. Jasinski DR, Martin WR (1967) Assessment of the dependence-producing properties of dihydrocodeinone and codoxime. Clin Pharmacol Ther 8:266-270
18. Kaplan HL, Busto UE, Baylon GJ, Cheung SW, Otton SV, Somer G, Sellers EM (1997) Inhibition of cytochrome P450 2D6 metabolism of hydrocodone to hydromorphone does not importantly affect abuse liability. J Pharmacol Exp Ther 281:103-108
19. Lelas S, Wegert S, Otton SV, Sellers EM, France CP (1999) Inhibitors of cytochrome P450 differentially modify discriminative-stimulus and antinociceptive effects of hydrocodone and hydromorphone in rhesus monkeys. Drug Alcohol Depend 54:239-249
20. Marken PA, Stoner SC, Bunker MT (1996) Anticholinergic drug abuse and misuse: Epidemiological and therapeutic implications. CNS Drugs 5:190-199
21. Martin WR, Sloan JW, Sapira JD, Jasinski DR (1971) Physiologic, subjective and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther 12:245-258
22. Mintzer MZ, Griffiths RR (1998) Flunitrazepam and triazolam: A comparison of behavioral effects and abuse liability. Drug Alcohol Depend 53:49-66
23. Morton HJ, Thomas ET (1958) Effect of atropin on the heart rate. Lancet 2:1313-1315
24. National Drug Intelligence Center (2001) Massachusetts Drug Threat Assessment: Other Dangerous Drugs. Website address: www.us-doj.gov/ndic/pubs/658/odd.htm
25. Nuotto EJ, Korttila K (1991) Evaluation of a new computerized psychomotor test battery: Effects of alcohol. Pharmacol Toxicol 68:360-365
26. O'Hanlon JF, Vermeeren A, Uiterwijk MMC, van Veggel LMA, Swijgman HF (1995) Anxiolytics' effects on the actual driving performance of patients and healthy volunteers in a standardized test. Neuropsychobiology 31:81-88
27. O'Neill WM, Hanks GW, White L, Simpson P, Wesnes K (1995) The cognitive and psychomotor effects of opioid analgesics I. A randomized controlled trial of single doses of dextropropoxyphene, lorazepam and placebo in healthy subjects. Eur J Clin Pharmacol 48:447-453
28. Osol A, Pratt R (eds) (1979) The United States Dispensatory, 27th Edn. Lippincott, Philadelphia, pp 586
29. Paivio A, Yulle JC, Madigan SA (1968) Concreteness, imagery, and meaningfulness values for 925 nouns. J Exp Psychol 76S:1-25
30. Petry NM, Bickel WK, Huddleston J, Tzanis E, Badger GJ (1998) A comparison of subjective, psychomotor and physiological effects of a novel muscarinic analgesic, LY297802 tartrate, and oral morphine in occasional drug users. Drug Alcohol Depend 50:129-136
31. Preston KL, Jasinski DR (1991) Abuse liability studies of opioid agonist-antagonists in humans. Drug Alcohol Depend 28:49-82
32. Preston KL, Bigelow GE, Bickel WK, Liebson IA (1989) Drug discrimination in human postaddicts: Agonist-antagonist opioids. J Pharmacol Exp Ther 250:184-196
33. Reisine T, Pasternak G (1996) Opioid analgesics and antagonists. In: Hardman JG, Gilman AG, Limbird LE (eds) Goodman and Gilman's the Pharmacological Basis of Therapeutics, 9th Edn. Pergamon Press, New York, pp 521-555
34. Seppala K, Korttila K, Hakkinene S, Linnoila M (1976) Residual effects and skills related to driving after a single oral administration of diazepam, medazepam or lorazepam. Br J Clin Pharmacol 3:831-841
35. Subhan Z, Harrison C, Hindmarch I (1986) Alprazolam and lorazepam: Single and multiple-dose effects on psychomotor skills and sleep. Eur J Clin Pharmacol 29:709-712
36. Substance Abuse and Mental Health Services Administration (2001) Summary of Findings from the 2000 National Household Survey of Drug Abuse. Office of Applied Studies, NHSDA Series H-13, DHHS Publication No. (SMA) 01-3549. Rockville, Md.
37. Substance Abuse and Mental Health Services Administration (2002) Emergency Department Trends from the Drug Abuse Warning Network, Preliminary Estimates January-June 2001 with Revised Estimates 1994 to 2000. Office of Applied Studies, DAWN Series D-20, DHHS Publication No. (SMA) 02-3634, Rockville, Md.
38. Thorndike EL, Lorge L (1944) The Teacher's Word Book of 30,000 Words. Columbia University Press, New York
39. Tomkins DM, Otton SV, Joharchi N, Li NY, Balster RF, Tyndale RF, Sellers EM (1997) Effect of cytochrome P450 2D1 inhibition on hydrocodone metabolism and its behavioral consequences in rats. J Pharmacol Exp Ther 280:1374-1382
40. Walker DJ, Zacny JP (1999) Subjective, psychomotor, and physiological effects of cumulative doses of opioid mu agonists in healthy volunteers. J Pharmacol Exp Ther 289:1454-1464
41. Walker DJ, Zacny JP (2001) Subjective, psychomotor, and physiological effects of cumulative doses of mixed-action agonists in healthy volunteers. Psychopharmacology 155:362-371
42. Wechsler D (1958) The Measurement and Appraisal of Adult Intelligence. Williams and Wilkins, Baltimore
43. Wetherell A (1996) Performance tests. Environ Health Perspect (Suppl 2) 104:247-273
44. Wilkinson CJ (1998) The abuse potential of zolpidem administered alone and with alcohol. Pharmacol Biochem Behav 60:193-202
45. Zacny JP (1995) A review of the effects of opiates on psychomotor and cognitive functioning in humans. Exp Clin Psychopharmacol 3:432-466
46. Zacny JP, Lichtor JL, Zaragoza JG, de Wit H (1992) Subjective and behavioral responses to intravenous fentanyl in healthy volunteers. Psychopharmacology 107:319-326
47. Zacny JP, Lichtor JL, Binstock W, Coalson DW, Cutter T, Flemming DC, Glosten B (1993) Subjective, behavioral and physiological responses to intravenous meperidine in healthy volunteers. Psychopharmacology 111:306-314
48. Zacny JP, Conley K, Galinkin J (1997a) Comparing the subjective, psychomotor and physiological effects of buprenorphine and morphine in healthy volunteers. J Pharmacol Exp Ther 282:1187-1197
49. Zacny JP, Conley K, Marks S (1997b) Comparing the subjective, psychomotor and physiological effects of intravenous nalbuphine and morphine in healthy volunteers. J Pharmacol Exp Ther 280:1159-1169